Ameliorative effect of mangiferin on high fat diet - Diethylnitrosamine induced non-alcoholic steatohepatitis rats

Non-alcoholic steatohepatitis (NASH) is a serious form of nonalcoholic fatty liver disease (NAFLD) which leads to fibrosis, cirrhosis and liver failure. This study is aimed to investigate the therapeutic effect of mangiferin, a major glucoxanthone of Mangifera indica L., on NASH. Pharmacokinetic property of mangiferin was assessed using DataWarrior tool and the compound was docked with PPAR alpha protein using Autodock tool. Anti-NASH efficacy of mangiferin was assessed in HFD-DEN induced Wistar rats at 50 and 100 mg/kg b. w. concentrations. Treatment with mangiferin significantly lowered plasma and liver lipid levels; it also reduced transaminase levels. The ultrasonography and histopathological studies showed reduction of steatosis and inflammation in the liver with mangiferin treatment. The treatment increased the hepatic mRNA expressions of PPAR alpha and FXR. These preliminary evidences gave an insight on the anti-NASH potential of mangiferin; further intensive studies are needed to establish it.

Automated summary

This study investigated the therapeutic effect of mangiferin on NASH, showing that mangiferin can lower liver lipid levels, reduce inflammation, and increase the expression of related genes, indicating its potential for treating NASH.